Methadone

This webinar provides essential insights into addressing the opioid overdose crisis and improving substance use care. It equips healthcare providers with evidence-based strategies for overdose prevention, including naloxone distribution, and explores innovative approaches to engage at-risk populations. Key topics include the role of substance use care providers and new methods to reduce overdose deaths.

As the opioid use crisis continues to progress, communities across the country are now being faced with additional dangers such as the misuse of Xylazine, a powerful sedative commonly used for animals in the drug supply. Recent studies indicate these potent substances when used with opioids increase overdose risk and complicates treatment and long-term healthcare. Join us today as we discuss the history and context of Xylazine and opioid use as well as options for treatment and care.

Shared decision-making (SDM) involves a collaborative discussion between the patient and clinician about treatment options, advantages and disadvantages, and helps to identify the optimal treatment based on patient-specific needs and goals.and helps to identify the optimal treatment based on patient-specific needs and goals.

Despite significant evidence of their effectiveness and efficacy, individuals across the country are still facing barriers to care associated with the stigma surrounding medications for opioid use disorder (MOUD). One recent peer-reviewed study found that of 360 facilities supporting individuals with opioid-related needs, one fourth were unwilling to serve individuals receiving MOUD (Kepple et al., 2019). For those seeking recovery housing, this unwillingness can mean choosing between their life-saving medications and a safe, supportive place to live.

Join our 4-session online case-based learning collaborative series focused on treating opioid use disorder. Delve into best practices on Hospital Based Approaches to OUD and explore real-world cases provided by addiction experts, applying knowledge to practical situations. Each session is presented live online and spans 1.5 hours.

Note: Once the live event has passed, please allow two weeks for the recording to be posted. Webinar Description: The treatment of opioid use disorder in rural communities can be challenging because of transportation, connectivity, and other barriers. Telemedicine can help with those barriers as well, but presents additional challenges. This talk will discuss some of the challenges related to the treatment of opioid use disorder in rural settings. We will discuss the benefits and pitfalls that come with the use of telemedicine. We will also discuss the challenges with obtaining urine toxicology screening and why it may not be a significant problem.

SAMHSA: Learn about the federal statutes, regulations, and guidelines that apply to medications for practitioners and opioid treatment programs (OTPs).

The Substance Abuse and Mental Health Services Administration (SAMHSA) has finalized an overhaul of opioid treatment programs (OTPs) that enshrines many flexibilities first implemented during the crisis response to the COVID pandemic. These changes represent the first significant change to methadone treatment in over 20 years. In this episode, we have Dr. Olsen return to our podcast to talk more about these important policy changes and what providers need to know. Dr. Yngvild Olsen is the director for the Center for Substance Abuse Treatment. 

Transitioning from jails and prisons back into the community can be especially difficult for people with opioid use disorders (OUD). Research suggests that opioid use overdose increases dramatically within the first 30 days of citizens returning to the community. Further, individuals recently released from incarceration face a risk of opioid overdose ten times greater than the general public. During these transitions it is critical that people receive seamless and appropriate resources in order to prevent overdose and return to use. This proper transition can help lower health care costs, hospitalizations and emergency department visits, as well as decrease mortality and recidivism for justice-involved individuals, yet at this time only 13 states have sought Medicaid waivers to provide SUD services pre-release. Join us today as we explore how programs can successfully develop services to ensure returning citizens receive appropriate care to address OUD.

Which patients receiving methadone should be considered good candidates for transfer to buprenorphine? How should I transition a patient from methadone to buprenorphine?